A 76-Year-Old Man With Recurrent Castrate-Sensitive Prostate Cancer

An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.

Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.

Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.

The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.

Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.

Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.

An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.

Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.